[{"id":"f43e758f-4bc3-4256-ae14-899721a6e9b8","acronym":"GALENT-BT","url":"https://clinicaltrials.gov/study/NCT06963060","created_at":"2025-09-07T01:31:36.203Z","updated_at":"2025-09-07T01:31:36.203Z","phase":"Phase 2","brief_title":"Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)","source_id_and_acronym":"NCT06963060 - GALENT-BT","lead_sponsor":"Wei Gong","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 44","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-05-08"},{"id":"876c2e70-4925-4835-9b88-46d9ace36858","acronym":"ComboMATCH Treatment Trial","url":"https://clinicaltrials.gov/study/NCT05564403","created_at":"2022-11-26T21:57:48.468Z","updated_at":"2025-02-25T13:41:17.315Z","phase":"Phase 2","brief_title":"Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)","source_id_and_acronym":"NCT05564403 - ComboMATCH Treatment Trial","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MAPK1","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["MAPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 02/09/2024","start_date":" 02/09/2024","primary_txt":" Primary completion: 01/21/2026","primary_completion_date":" 01/21/2026","study_txt":" Completion: 01/21/2026","study_completion_date":" 01/21/2026","last_update_posted":"2025-02-21"},{"id":"9ae6d61c-52ac-447d-9656-ee355853d0dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04068194","created_at":"2023-11-15T17:14:49.418Z","updated_at":"2025-02-25T13:52:57.960Z","phase":"Phase 1/2","brief_title":"Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies","source_id_and_acronym":"NCT04068194","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB","pipe":"","alterations":" ","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • peposertib (M3814)"],"overall_status":"Recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 04/07/2020","start_date":" 04/07/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-20"},{"id":"56fa4122-48b0-496d-9b08-3036a6a23a21","acronym":"TACTIC-3","url":"https://clinicaltrials.gov/study/NCT05862324","created_at":"2023-05-17T14:05:21.313Z","updated_at":"2025-02-25T14:42:02.177Z","phase":"Phase 1/2","brief_title":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)","source_id_and_acronym":"NCT05862324 - TACTIC-3","lead_sponsor":"Triumvira Immunologics, Inc.","biomarkers":" EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation","tags":["EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • TAC101-Claudin18.2"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 113","initiation":"Initiation: 08/23/2023","start_date":" 08/23/2023","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-02-14"},{"id":"6c9db75b-36fc-4c6c-ad67-8b4c2281f714","acronym":"MRD-GI","url":"https://clinicaltrials.gov/study/NCT05482516","created_at":"2022-08-01T14:54:43.578Z","updated_at":"2025-02-25T15:12:57.370Z","phase":"Phase 3","brief_title":"Evaluating Novel Therapies in ctDNA Positive GI Cancers","source_id_and_acronym":"NCT05482516 - MRD-GI","lead_sponsor":"Georgetown University","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/29/2023","start_date":" 03/29/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-02-13"},{"id":"231092fb-00ef-4553-bd1a-e401bd09459d","acronym":"LITESPARK-016","url":"https://clinicaltrials.gov/study/NCT04976634","created_at":"2021-07-26T17:53:23.648Z","updated_at":"2025-02-25T15:19:12.763Z","phase":"Phase 2","brief_title":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)","source_id_and_acronym":"NCT04976634 - LITESPARK-016","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Welireg (belzutifan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 730","initiation":"Initiation: 08/18/2021","start_date":" 08/18/2021","primary_txt":" Primary completion: 03/22/2027","primary_completion_date":" 03/22/2027","study_txt":" Completion: 03/22/2027","study_completion_date":" 03/22/2027","last_update_posted":"2025-02-12"},{"id":"9518cf2f-a488-48b8-a437-c584bd916e0c","acronym":"Brightline-2","url":"https://clinicaltrials.gov/study/NCT05512377","created_at":"2022-08-23T14:55:35.585Z","updated_at":"2025-02-25T15:19:58.742Z","phase":"Phase 2","brief_title":"Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder","source_id_and_acronym":"NCT05512377 - Brightline-2","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 12/13/2022","start_date":" 12/13/2022","primary_txt":" Primary completion: 06/10/2025","primary_completion_date":" 06/10/2025","study_txt":" Completion: 06/10/2025","study_completion_date":" 06/10/2025","last_update_posted":"2025-02-11"},{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2025-02-25T16:36:45.708Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-06"},{"id":"f231b1ba-c963-4fcd-a957-1503f6a6f741","acronym":"SGNTUC 024","url":"https://clinicaltrials.gov/study/NCT04430738","created_at":"2021-01-18T21:20:17.873Z","updated_at":"2025-02-25T16:37:54.749Z","phase":"Phase 1/2","brief_title":"Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers","source_id_and_acronym":"NCT04430738 - SGNTUC 024","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • 5-fluorouracil • capecitabine • oxaliplatin • Tukysa (tucatinib) • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 09/15/2020","start_date":" 09/15/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-02-06"},{"id":"235d782d-2e73-4b08-9fbb-54173c4ba4b6","acronym":"HERBOT","url":"https://clinicaltrials.gov/study/NCT05749900","created_at":"2023-03-01T15:02:12.876Z","updated_at":"2025-02-25T16:46:38.516Z","phase":"Phase 1/2","brief_title":"First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)","source_id_and_acronym":"NCT05749900 - HERBOT","lead_sponsor":"Yonsei University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Herceptin (trastuzumab) • cisplatin • gemcitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 05/12/2023","start_date":" 05/12/2023","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-02-05"},{"id":"73183b76-400c-42da-8908-2c1fc21637ec","acronym":"OPTIMUM","url":"https://clinicaltrials.gov/study/NCT05222971","created_at":"2022-02-05T18:29:24.003Z","updated_at":"2025-02-25T17:37:35.916Z","phase":"Phase 2","brief_title":"Olaparib with or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy","source_id_and_acronym":"NCT05222971 - OPTIMUM","lead_sponsor":"Asan Medical Center","biomarkers":" BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1","pipe":" | ","alterations":" ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation","tags":["BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-01-28"},{"id":"a4ed02c4-6f06-4ed4-a5b9-d63c7176c2eb","acronym":"LEAP-005","url":"https://clinicaltrials.gov/study/NCT03797326","created_at":"2021-01-17T17:13:36.138Z","updated_at":"2025-02-25T13:35:11.465Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)","source_id_and_acronym":"NCT03797326 - LEAP-005","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 603","initiation":"Initiation: 02/12/2019","start_date":" 02/12/2019","primary_txt":" Primary completion: 10/28/2024","primary_completion_date":" 10/28/2024","study_txt":" Completion: 10/28/2024","study_completion_date":" 10/28/2024","last_update_posted":"2024-11-15"},{"id":"0d376833-0db0-4c3f-a481-a0fdb012621c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04449549","created_at":"2021-01-18T21:24:29.334Z","updated_at":"2024-07-02T16:34:25.844Z","phase":"Phase 2","brief_title":"Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel","source_id_and_acronym":"NCT04449549","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • nilotinib"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 08/24/2020","start_date":" 08/24/2020","primary_txt":" Primary completion: 04/02/2025","primary_completion_date":" 04/02/2025","study_txt":" Completion: 04/08/2025","study_completion_date":" 04/08/2025","last_update_posted":"2024-06-14"},{"id":"f9f357c2-8949-408a-8e82-24a82b424f06","acronym":"EVER-132-003","url":"https://clinicaltrials.gov/study/NCT05119907","created_at":"2023-03-03T17:01:47.232Z","updated_at":"2024-07-02T16:34:25.825Z","phase":"Phase 2","brief_title":"Study of Sacituzumab Govitecan in Patients With Solid Tumor","source_id_and_acronym":"NCT05119907 - EVER-132-003","lead_sponsor":"Gilead Sciences","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 10/12/2021","start_date":" 10/12/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-06-14"},{"id":"a3d44513-3d22-4617-a3e3-b78c69f0ade8","acronym":"SGNB7H4V-001","url":"https://clinicaltrials.gov/study/NCT05194072","created_at":"2022-01-18T12:54:03.783Z","updated_at":"2024-07-02T16:34:27.305Z","phase":"Phase 1","brief_title":"A Study of SGN-B7H4V in Advanced Solid Tumors","source_id_and_acronym":"NCT05194072 - SGNB7H4V-001","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • PTEN mutation + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e felmetatug vedotin (PF-08046048)"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 01/12/2022","start_date":" 01/12/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-06-11"},{"id":"28ed5efa-c5b5-4262-aa3e-54b883b60ead","acronym":"ARTISTRY-3","url":"https://clinicaltrials.gov/study/NCT04592653","created_at":"2021-01-19T20:28:47.499Z","updated_at":"2024-07-02T16:34:37.223Z","phase":"Phase 1/2","brief_title":"Less Frequent IV Dosing \u0026 Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)","source_id_and_acronym":"NCT04592653 - ARTISTRY-3","lead_sponsor":"Mural Oncology, Inc","biomarkers":" MSI • NCAM1","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • nemvaleukin alfa (ALKS 4230)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 09/30/2020","start_date":" 09/30/2020","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-07"},{"id":"285e0fae-6b50-4026-b6af-15e5137223d2","acronym":"ZWI-ZW25-201","url":"https://clinicaltrials.gov/study/NCT03929666","created_at":"2021-01-18T19:21:37.373Z","updated_at":"2024-07-02T16:34:37.769Z","phase":"Phase 2","brief_title":"A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer","source_id_and_acronym":"NCT03929666 - ZWI-ZW25-201","lead_sponsor":"Jazz Pharmaceuticals","biomarkers":" HER-2 • KRAS • BRAF • NRAS • RAS","pipe":" | ","alterations":" HER-2 amplification • HER-2 expression • KRAS wild-type • BRAF wild-type • NRAS wild-type","tags":["HER-2 • KRAS • BRAF • NRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 expression • KRAS wild-type • BRAF wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • gemcitabine • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • Ziihera (zanidatamab-hrii)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 08/29/2019","start_date":" 08/29/2019","primary_txt":" Primary completion: 11/28/2025","primary_completion_date":" 11/28/2025","study_txt":" Completion: 10/30/2026","study_completion_date":" 10/30/2026","last_update_posted":"2024-06-06"},{"id":"4f044f18-3e23-4009-90ad-d13973fbf09d","acronym":"KEYNOTE-158","url":"https://clinicaltrials.gov/study/NCT02628067","created_at":"2021-01-17T17:22:08.805Z","updated_at":"2024-07-02T16:35:04.350Z","phase":"Phase 2","brief_title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","source_id_and_acronym":"NCT02628067 - KEYNOTE-158","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" TMB • MSI","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR","tags":["TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 1609","initiation":"Initiation: 12/18/2015","start_date":" 12/18/2015","primary_txt":" Primary completion: 05/04/2027","primary_completion_date":" 05/04/2027","study_txt":" Completion: 05/04/2027","study_completion_date":" 05/04/2027","last_update_posted":"2024-05-10"},{"id":"f1eb15be-99b0-4993-89d8-1f3e74e59506","acronym":"","url":"https://clinicaltrials.gov/study/NCT05297903","created_at":"2022-03-28T13:52:59.235Z","updated_at":"2024-07-02T16:35:05.357Z","phase":"Phase 2","brief_title":"XmAb20717 in Advanced Biliary Tract Cancers","source_id_and_acronym":"NCT05297903","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" FGFR2 • IDH1 • NTRK","pipe":" | ","alterations":" IDH1 mutation • FGFR2 mutation • FGFR2 fusion • NTRK fusion","tags":["FGFR2 • IDH1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • FGFR2 mutation • FGFR2 fusion • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vudalimab (XmAb717)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-07"},{"id":"1724693c-3f92-4147-a8fc-47d82f80159d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04742959","created_at":"2023-12-01T18:15:51.667Z","updated_at":"2024-07-02T16:35:07.274Z","phase":"Phase 1/2","brief_title":"Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04742959","lead_sponsor":"TransThera Sciences (Nanjing), Inc.","biomarkers":" FGFR","pipe":"","alterations":" ","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • tinengotinib (TT-00420)"],"overall_status":"Completed","enrollment":" Enrollment 203","initiation":"Initiation: 03/14/2021","start_date":" 03/14/2021","primary_txt":" Primary completion: 02/20/2024","primary_completion_date":" 02/20/2024","study_txt":" Completion: 02/20/2024","study_completion_date":" 02/20/2024","last_update_posted":"2024-04-26"},{"id":"87f0861a-71c2-4555-9071-1764face39ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT04641871","created_at":"2021-08-24T14:53:56.048Z","updated_at":"2024-07-02T16:35:07.851Z","phase":"Phase 1","brief_title":"Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies","source_id_and_acronym":"NCT04641871","lead_sponsor":"Symphogen A/S","biomarkers":" FGFR2 • IDH1","pipe":" | ","alterations":" IDH1 mutation • FGFR2 mutation • FGFR2 fusion","tags":["FGFR2 • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • FGFR2 mutation • FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • S95018 • Sym021 • Sym022"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 10/12/2020","start_date":" 10/12/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-04-24"},{"id":"9d8b6c93-08dc-4970-81f2-d1128b31ecbe","acronym":"PLATON","url":"https://clinicaltrials.gov/study/NCT04484636","created_at":"2021-01-18T21:31:54.959Z","updated_at":"2024-07-02T16:35:07.931Z","phase":"","brief_title":"PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)","source_id_and_acronym":"NCT04484636 - PLATON","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" TMB • MSI","pipe":"","alterations":" ","tags":["TMB • MSI"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 10/28/2020","start_date":" 10/28/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 07/30/2024","study_completion_date":" 07/30/2024","last_update_posted":"2024-04-23"},{"id":"46d378ac-a32a-49b5-8f63-3c539b277a13","acronym":"QPCS","url":"https://clinicaltrials.gov/study/NCT04104230","created_at":"2021-01-18T20:04:23.369Z","updated_at":"2024-07-02T16:35:09.050Z","phase":"","brief_title":"Quebec Pancreas Cancer Study","source_id_and_acronym":"NCT04104230 - QPCS","lead_sponsor":"George Zogopoulos","biomarkers":" BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1","pipe":" | ","alterations":" ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 03/12/2012","start_date":" 03/12/2012","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-04-17"},{"id":"a0f9dd51-d692-4574-b05e-3f5caa78cfd2","acronym":"AMPLIFY-201","url":"https://clinicaltrials.gov/study/NCT04853017","created_at":"2021-04-21T11:53:35.333Z","updated_at":"2024-07-02T16:35:09.637Z","phase":"Phase 1","brief_title":"A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors","source_id_and_acronym":"NCT04853017 - AMPLIFY-201","lead_sponsor":"Elicio Therapeutics","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS G12D • KRAS G12 • NRAS G12D • NRAS G12","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS G12D • KRAS G12 • NRAS G12D • NRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ELI-002 7P • Promune (agatolimod)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 10/04/2021","start_date":" 10/04/2021","primary_txt":" Primary completion: 01/26/2023","primary_completion_date":" 01/26/2023","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-15"}]